Recent advances in bacteria‐based platforms for inflammatory bowel diseases treatment
Open Access
- 5 March 2024
- journal article
- review article
- Published by Wiley in Exploration
- Vol. 4 (5) , 20230142
Abstract
Inflammatory bowel disease (IBD) is a recurring chronic inflammatory disease. Current treatment strategies are aimed at alleviating clinical symptoms and are associated with gastrointestinal or systemic adverse effects. New delivery strategies are needed for the treatment of IBD. Bacteria are promising biocarriers, which can produce drugs in situ and sense the gut in real time. Herein, we focus on recent studies of engineered bacteria used for IBD treatment and introduce the application of engineered bacteria in the diagnosis. On this basis, the current dilemmas and future developments of bacterial delivery systems are discussed.Keywords
Funding Information
- National Natural Science Foundation of China (82000489)
This publication has 138 references indexed in Scilit:
- Oral Nanomedicine: Challenges and OpportunitiesAdvanced Materials, 2023
- mRNA nanomedicine: Design and recent applicationsExploration, 2022
- Recent applications of immunomodulatory biomaterials for disease immunotherapyExploration, 2022
- Organic fluorescent nanoprobes with NIR‐IIb characteristics for deep learningExploration, 2022
- Polydopamine Nanoparticle‐Mediated Dopaminergic Immunoregulation in ColitisAdvanced Science, 2021
- Nanozyme for tumor therapy: Surface modification mattersExploration, 2021
- An engineered probiotic secreting Sj16 ameliorates colitis via Ruminococcaceae/butyrate/retinoic acid axisBioengineering & Translational Medicine, 2021
- Genetically Programmable Self‐Regenerating Bacterial HydrogelsAdvanced Materials, 2019
- Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative ColitisJAMA, 2019
- Cancer risk in patients with inflammatory bowel diseaseCancer, 2001